



PEARL

International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process

Hobart, J; Bowen, A; Eberhard, L; Pepper, G; Giovannoni, G

DOI:

[10.1111/ene.13700](https://doi.org/10.1111/ene.13700)

Publication date:

2018

Link:

[Link to publication in PEARL](#)

Citation for published version (APA):

Hobart, J., Bowen, A., Eberhard, L., Pepper, G., & Giovannoni, G. (2018). *International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process*. <https://doi.org/10.1111/ene.13700>

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Wherever possible please cite the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process

J. Hobart 1, A. Bowen 2, L. Eberhard 3, G. Pepper 4, G. Giovannoni 5

1 Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom,

2 NHS RightCare, London, United Kingdom,

3 PharmaGenesis London, London, United Kingdom,

4 Shift.ms, Leeds, United Kingdom,

5 Queen Mary University of London, London, United Kingdom

Background and aims: The importance of prompt intervention in multiple sclerosis (MS) was described in the widely endorsed report, Brain health: time matters in multiple sclerosis.¹ The present study aimed to define standards for the timing of key steps in the care pathway.

Methods: An international group of 29 MS neurologists was recruited to participate in a Delphi process. Across five rounds, they defined 'core', 'achievable' and 'aspirational' standards (to reflect a minimum, good and high standard of MS care, respectively). A Reviewing Group of 31 MS nurses, experts with MS and allied healthcare professionals reviewed the results and provided feedback.

Results: Consensus was reached ($\geq 75\%$ agreement; $n=21$) on core, achievable and aspirational standards for 21 steps in the MS care pathway, covering symptom onset, referral, diagnosis, treatment decisions, lifestyle, monitoring, and managing new symptoms. For example, the panel agreed that MS teams should complete a diagnostic workup for MS within 2 months of referral to a neurologist as a core standard, and that completion within 4 weeks of referral should be achievable for most MS teams, with completion within 7 days as an aspirational standard. Here, we will present core, achievable and aspirational standards for key steps in the MS care pathway.

Conclusion: These standards will inform tools for clinics and people with MS and act as a future benchmark for established and developing MS clinics across the globe aiming to deliver the highest quality care. Reference 1. Giovannoni G et al. *Mult Scler Relat Disord* 2016;9 Suppl 1:S5–S48.

Disclosure: J. Hobart has received consulting fees, honoraria, support to attend meetings or research support from Acorda, Asubio, Bayer Schering, Biogen Idec, F. Hoffmann-La Roche, Genzyme, Merck Serono, Novartis, Oxford PharmaGenesis and Teva. A Bowen has nothing to disclose. L. Eberhard is an employee of PharmaGenesis London. G. Pepper has received consulting fees from Biogen, Novartis, Oxford PharmaGenesis and Teva. G. Giovannoni has received consulting fees from AbbVie, Atara Biotherapeutics, Almirall, Biogen, Celgene, GlaxoSmithKline, MedDay Pharmaceuticals, Merck and Company (US), Merck Group (Europe), Novartis, Oxford PharmaGenesis, Roche, Sanofi Genzyme, Synthron, Takeda, Teva Pharmaceutical Industries Ltd., UCB; and grant/ research support from Biogen, Sanofi Genzyme, Takeda.